FREEHOLD, N.J., Dec. 8, 2005 (PRIMEZONE) -- New Life Scientific, Inc. (OTCBB:NWLF) announced today that a speculative buy rating has been issued by Spelman Research, an investment research firm. Quoting from the report, Stelian Mitu, MBA, CFA, stated, "We initiated coverage on NWLF believing that the company has now an interesting portfolio of drug development projects, clinical trial capabilities and good access to stem cells research expertise, and assigned a Speculative Buy rating to the company. We believe there is a fair chance that despite the highly speculative nature, NWLF could be the next Genentech if NWLF gets adequate financing and if stem cells research projects materialize into effective treatments as NWLF owns a CRO division that already started to produce revenues, we believe NWLF is in a better position than most of its development-state peers researching stem cells." The 53 page report is available online at www.spelmanresearch.com.
About Spellman Research
Spelman Research is an independent research organization that has assembled a team of experienced securities analysts in order to offer expert, un-biased fundamental research on under-followed growth public companies http://www.spelmanresearch.com/learn-about-investment-research.html
Spelman research has been paid $26,500 by Emerging Markets Consulting, LLC for 12 months of coverage on NWLF.
Emerging Markets Consulting, LLC provides Public Relations/Investor Relations Services for NWLF.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.